Frazier Life Sciences IX, L.P. 4
4 · Mirum Pharmaceuticals, Inc. · Filed Jul 24, 2019
Insider Transaction Report
Form 4
Frazier Life Sciences IX, L.P.
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2019-07-22−24,935,300→ 0 total→ Common Stock (3,116,912 underlying) - Purchase
Common Stock
2019-07-22$15.00/sh+450,000$6,750,000→ 3,566,912 total - Conversion
Common Stock
2019-07-22+3,116,912→ 3,116,912 total
Footnotes (3)
- [F1]In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date.
- [F2]The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
- [F3]The shares were purchased in the Issuer's initial public offering.